HIV对住院患者COVID-19死亡风险的影响

Q3 Medicine

Human Antibodies Pub Date : 2022-01-01 DOI:10.3233/HAB-220011

Mehdi Azizmohammad Looha, Nazanin Taraghikhah, Maedeh Amini, Pegah Salimi Pormehr, Negin Talaei, Mahmood Khodadoost, Saeid Gholamzadeh, Reza Vafaee, Gohar Mohammadi

{"title":"HIV对住院患者COVID-19死亡风险的影响","authors":"Mehdi Azizmohammad Looha, Nazanin Taraghikhah, Maedeh Amini, Pegah Salimi Pormehr, Negin Talaei, Mahmood Khodadoost, Saeid Gholamzadeh, Reza Vafaee, Gohar Mohammadi","doi":"10.3233/HAB-220011","DOIUrl":null,"url":null,"abstract":"Background: Little is known about the association between Human Immunodeficiency Virus (HIV) infection and risk of death among hospitalized COVID-19 patients. We aimed to investigate this association using a multicenter study.Material and methods: This multicenter study was conducted using the registry database of Coronavirus Control Operations Headquarter from March 21, 2021 to January 18, 2020 in the province of Tehran, Iran. The interest outcome was COVID-19 death among hospitalized patients living with and without HIV. The Cox regression models with robust standard error were used to estimate the association between HIV infection and risk of COVID-19 death. The subgroup and interaction analysis were also performed in this study.Results: 326052 patients with COVID-19 were included in the study, of whom 127 (0.04%) were living with HIV. COVID-19 patients with HIV were more likely to be female, older, and to have symptoms such as fever, muscular pain, dyspnea and cough. The death proportion due to COVID-19 was 18 (14.17%) and 21595 (6.63%) among HIV and non-HIV patients, respectively. Patients living with HIV had lower mean survival time compared to those without HIV (26.49 vs. 15.31 days, P-value = 0.047). Crude risk of COVID-19 death was higher among HIV patients than in non-HIV group (hazard ratio[HR]: 1.60, 1.08-2.37). Compared to those without HIV, higher risk of COVID-19 death was observed among patients with HIV after adjusting for sex (1.60, 1.08-2.36), comorbidities (1.49, 1.01-2.19), cancer (1.59, 1.08-2.33), and PO2 (1.68, 1.12-2.50). However, the risk of COVID-19 death was similar in patients with and without HIV after adjusting for age (1.46, 0.98-2.16) and ward (1.30, 0.89-1.89).Conclusion: We found no strong evidence of association between HIV infection and higher risk of COVID-19 death among hospitalized patients. To determine the true impact of HIV on the risk of COVID-19 death, factors such as age, comorbidities, hospital ward, viral load, CD4 count, and antiretroviral treatment should be considered.","PeriodicalId":53564,"journal":{"name":"Human Antibodies","volume":"30 4","pages":"165-175"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The impact of HIV on the risk of COVID-19 death among hospitalized patients.\",\"authors\":\"Mehdi Azizmohammad Looha, Nazanin Taraghikhah, Maedeh Amini, Pegah Salimi Pormehr, Negin Talaei, Mahmood Khodadoost, Saeid Gholamzadeh, Reza Vafaee, Gohar Mohammadi\",\"doi\":\"10.3233/HAB-220011\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Little is known about the association between Human Immunodeficiency Virus (HIV) infection and risk of death among hospitalized COVID-19 patients. We aimed to investigate this association using a multicenter study.Material and methods: This multicenter study was conducted using the registry database of Coronavirus Control Operations Headquarter from March 21, 2021 to January 18, 2020 in the province of Tehran, Iran. The interest outcome was COVID-19 death among hospitalized patients living with and without HIV. The Cox regression models with robust standard error were used to estimate the association between HIV infection and risk of COVID-19 death. The subgroup and interaction analysis were also performed in this study.Results: 326052 patients with COVID-19 were included in the study, of whom 127 (0.04%) were living with HIV. COVID-19 patients with HIV were more likely to be female, older, and to have symptoms such as fever, muscular pain, dyspnea and cough. The death proportion due to COVID-19 was 18 (14.17%) and 21595 (6.63%) among HIV and non-HIV patients, respectively. Patients living with HIV had lower mean survival time compared to those without HIV (26.49 vs. 15.31 days, P-value = 0.047). Crude risk of COVID-19 death was higher among HIV patients than in non-HIV group (hazard ratio[HR]: 1.60, 1.08-2.37). Compared to those without HIV, higher risk of COVID-19 death was observed among patients with HIV after adjusting for sex (1.60, 1.08-2.36), comorbidities (1.49, 1.01-2.19), cancer (1.59, 1.08-2.33), and PO2 (1.68, 1.12-2.50). However, the risk of COVID-19 death was similar in patients with and without HIV after adjusting for age (1.46, 0.98-2.16) and ward (1.30, 0.89-1.89).Conclusion: We found no strong evidence of association between HIV infection and higher risk of COVID-19 death among hospitalized patients. To determine the true impact of HIV on the risk of COVID-19 death, factors such as age, comorbidities, hospital ward, viral load, CD4 count, and antiretroviral treatment should be considered.\",\"PeriodicalId\":53564,\"journal\":{\"name\":\"Human Antibodies\",\"volume\":\"30 4\",\"pages\":\"165-175\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Human Antibodies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3233/HAB-220011\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Antibodies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3233/HAB-220011","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

背景:人类免疫缺陷病毒(HIV)感染与住院COVID-19患者死亡风险之间的关系尚不清楚。我们的目的是通过一项多中心研究来调查这种关联。材料和方法:本多中心研究于2021年3月21日至2020年1月18日在伊朗德黑兰省利用冠状病毒控制行动总部的登记数据库进行。感兴趣的结局是感染和不感染艾滋病毒的住院患者中COVID-19死亡。使用具有稳健标准误差的Cox回归模型来估计HIV感染与COVID-19死亡风险之间的关联。本研究还进行了亚组分析和相互作用分析。结果:共纳入326052例COVID-19患者，其中127例(0.04%)为HIV感染者。COVID-19感染艾滋病毒的患者更有可能是女性、年龄较大，并出现发烧、肌肉疼痛、呼吸困难和咳嗽等症状。在HIV和非HIV患者中，因COVID-19死亡的比例分别为18例(14.17%)和21595例(6.63%)。HIV感染者的平均生存时间比未感染HIV的患者低(26.49天比15.31天，p值= 0.047)。HIV患者的COVID-19粗死亡风险高于非HIV组(风险比:1.60,1.08-2.37)。经性别(1.60,1.08-2.36)、合并症(1.49,1.01-2.19)、癌症(1.59,1.08-2.33)和PO2(1.68, 1.12-2.50)校正后，HIV患者的COVID-19死亡风险高于未感染HIV的患者。然而，在调整年龄(1.46,0.98-2.16)和病房(1.30,0.89-1.89)后，感染和未感染艾滋病毒的患者的COVID-19死亡风险相似。结论:我们未发现住院患者中HIV感染与COVID-19死亡风险较高之间存在强有力的关联。要确定艾滋病毒对COVID-19死亡风险的真正影响，应考虑年龄、合并症、医院病房、病毒载量、CD4计数和抗逆转录病毒治疗等因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The impact of HIV on the risk of COVID-19 death among hospitalized patients.

Background: Little is known about the association between Human Immunodeficiency Virus (HIV) infection and risk of death among hospitalized COVID-19 patients. We aimed to investigate this association using a multicenter study.

Material and methods: This multicenter study was conducted using the registry database of Coronavirus Control Operations Headquarter from March 21, 2021 to January 18, 2020 in the province of Tehran, Iran. The interest outcome was COVID-19 death among hospitalized patients living with and without HIV. The Cox regression models with robust standard error were used to estimate the association between HIV infection and risk of COVID-19 death. The subgroup and interaction analysis were also performed in this study.

Results: 326052 patients with COVID-19 were included in the study, of whom 127 (0.04%) were living with HIV. COVID-19 patients with HIV were more likely to be female, older, and to have symptoms such as fever, muscular pain, dyspnea and cough. The death proportion due to COVID-19 was 18 (14.17%) and 21595 (6.63%) among HIV and non-HIV patients, respectively. Patients living with HIV had lower mean survival time compared to those without HIV (26.49 vs. 15.31 days, P-value = 0.047). Crude risk of COVID-19 death was higher among HIV patients than in non-HIV group (hazard ratio[HR]: 1.60, 1.08-2.37). Compared to those without HIV, higher risk of COVID-19 death was observed among patients with HIV after adjusting for sex (1.60, 1.08-2.36), comorbidities (1.49, 1.01-2.19), cancer (1.59, 1.08-2.33), and PO2 (1.68, 1.12-2.50). However, the risk of COVID-19 death was similar in patients with and without HIV after adjusting for age (1.46, 0.98-2.16) and ward (1.30, 0.89-1.89).

Conclusion: We found no strong evidence of association between HIV infection and higher risk of COVID-19 death among hospitalized patients. To determine the true impact of HIV on the risk of COVID-19 death, factors such as age, comorbidities, hospital ward, viral load, CD4 count, and antiretroviral treatment should be considered.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Human Antibodies Medicine-Immunology and Allergy

CiteScore

3.50

自引率

0.00%

发文量

期刊介绍： Human Antibodies is an international journal designed to bring together all aspects of human hybridomas and antibody technology under a single, cohesive theme. This includes fundamental research, applied science and clinical applications. Emphasis in the published articles is on antisera, monoclonal antibodies, fusion partners, EBV transformation, transfections, in vitro immunization, defined antigens, tissue reactivity, scale-up production, chimeric antibodies, autoimmunity, natural antibodies/immune response, anti-idiotypes, and hybridomas secreting interesting growth factors. Immunoregulatory molecules, including T cell hybridomas, will also be featured.